|Dr. Raymond De Vre Ph.D.||Chief Exec. Officer||無||無||1968|
|Mr. Jan Fuhr Miller||Chief Financial Officer||無||無||無|
|Mr. Daniel Lasanow||Director of Global Operations||無||無||無|
|Mr. Michael Staheli||Head of Investor Relations & Corp. Communications||無||無||無|
|Ms. Christina Del Vecchio||Gen. Counsel & Corp. Sec.||無||無||1978|
|Mr. Jan Christensen||Global Director of Sales & Marketing||無||無||1960|
PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides for use in pre-clinical and clinical development, as well as for regulatory and scientific studies; and developing neoantigen therapies as personalized immunotherapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics; and provision of consultation services. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland.
截至 無 止，PolyPeptide Group AG 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。